Pushing the genetic frontier with facioscapulohumeral muscular dystrophy
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Facioscapulohumeral muscular dystrophy (FSHD) is an enigmatic genetic disorder with consistent major effects on skeletal muscle and less consistent effects on other tissues. Although the location of a causative genetic disturbance has been identified at one end of chromosome 4, the full nature of the disturbance and how this produces the disease is unclear. The study of the relationship between the genetic abnormalities present and the production of disease in FSHD promises not only to benefit the care of patients with FSHD and further our understanding of skeletal muscle biology, but also to shed fundamental light on basic mechanisms of gene regulation and human genetics.
The genetic disturbance present in almost all people with FSHD is of a peculiar nature. It consists of an uncommon deletion of a region at the distal end of chromosome 4q combined with the presence of one of two common sequence variants distal to this deleted region. Both are necessary. Furthermore, unlike the majority of other genetic disorders, the mutant FSHD deleted region does not include any known transcribed sequences. In this issue of Neurology, two articles advance our understanding of FSHD.1,2 One provides compelling data pertaining to a new hypothesis for the disease mechanism and insight into the relationship between gene expression and nonmuscle systemic disease in FSHD, and the other adds to defining the minimal genetic requirement for the disease.
The article by Osborne …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.